Trial Profile
A Single-dose, Open-label, Parallel-group Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Subjects With Varying Degrees of Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Apr 2019 Status changed from recruiting to completed.
- 29 Jun 2018 Status changed from not yet recruiting to recruiting.
- 11 Jun 2018 New trial record